- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | Altamira Therapeutics GAAP EPS of -$0.55 | 2 | Seeking Alpha | ||
| ALTAMIRA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 31.03. | Altamira Therapeutics Ltd.: Altamira Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results | 195 | ACCESS Newswire | Expanding nucleic acid delivery business with new applicationsOngoing optimization of cost structureAdvancing plans for spin-off of nucleic acid delivery business and continuing strategic repositioning... ► Artikel lesen | |
| 24.03. | Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Release Date for 2025 Annual Report and Financial Statements | 172 | ACCESS Newswire | HAMILTON, BM / ACCESS Newswire / March 24, 2026 / Altamira Therapeutics ("Altamira" or the "Company") (OTCID:CYTOF) today announced that it will release its annual report and financial statements for... ► Artikel lesen | |
| 13.02. | Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Bentrio Nasal Spray | 440 | ACCESS Newswire | HAMILTON, BM / ACCESS Newswire / February 13, 2026 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCID:CYTOF), a company dedicated to developing and supplying nucleic acid delivery technology... ► Artikel lesen | |
| 23.01. | Altamira Therapeutics Ltd.: Altamira Therapeutics to Present at mRNA-Based Therapeutics Summit | 557 | ACCESS Newswire | HAMILTON, BERMUDA / ACCESS Newswire / January 23, 2026 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCID:CYTOF), a company dedicated to developing and commercializing nucleic acid delivery... ► Artikel lesen | |
| 19.12.25 | Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Market Approval of Bentrio Nasal Spray in China | 433 | ACCESS Newswire | Regulatory clearance of Bentrio in allergic rhinitis for Mainland ChinaNearly 200 million Chinese estimated to suffer from allergic rhinitisBentrio to be launched by partner Nuance Pharma HAMILTON,... ► Artikel lesen | |
| 20.11.25 | Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Certification of Bentrio Nasal Spray under Medical Device Regulation | 718 | ACCESS Newswire | Conformity with stringent new EU regulations for medical devices confirmedAllows for commercialization of Bentrio in EU member states; facilitates regulatory approval in various other countriesMajor... ► Artikel lesen | |
| 03.11.25 | Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of DNA Molecules | 331 | ACCESS Newswire | Demonstrated feasibility of effective DNA delivery with Company's xPhore nanoparticle technologyDNA delivery technology to be offered as GenePhore to biotech / pharma companiesAddressing large and growing... ► Artikel lesen | |
| 29.08.25 | Altamira Therapeutics Provides Business Update and First Half 2025 Financial Results | 749 | ACCESS Newswire | Company to host webcast today at 8.00 a.m. ETGrowing portfolio of RNA delivery clients and programsAdvancing plans for partial spin-off of RNA delivery activitiesContinued adjustment of cost structure... ► Artikel lesen | |
| 26.08.25 | Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025 | 411 | ACCESS Newswire | HAMILTON, BERMUDA / ACCESS Newswire / August 26, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology... ► Artikel lesen | |
| 15.07.25 | Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Intranasal Betahistine | 285 | ACCESS Newswire | HAMILTON, BM / ACCESS Newswire / July 15, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing therapeutics that address important unmet medical... ► Artikel lesen | |
| 11.06.25 | Delisting of Securities of Blue Star Foods Corp.; Altamira Therapeutics Ltd.; Evergreen Corporation; Fresh2 Group Limited; Coliseum Acquisition Corp.; The Real Good Food Company, Inc.; Mynaric AG; byNordic Acquisition Corporation; ... | 973 | GlobeNewswire (Europe) | NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of Blue Star Foods Corp. Blue Star Foods Corp.'s stock was suspended on December... ► Artikel lesen | |
| 30.04.25 | Altamira Therapeutics Ltd: Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results | 516 | GlobeNewswire (Europe) | Hamilton, Bermuda, April 30, 2025 (GLOBE NEWSWIRE) -- Management to host conference call today, April 30, at 8:00 a.m. EDTRNA delivery business progressing with platform development, new applications... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,40 | -0,06 % | BioNTech, Newron und Emyria: Biotech-Unternehmen rücken in den Fokus einer neuen Substanzdebatte | ||
| EVOTEC | 4,530 | +0,09 % | Evotec-Aktie profitiert von Milliarden-Deal: Gilead kauft Tubulis | Der US-Pharmakonzern Gilead setzt seine Einkaufstour im Biotech-Sektor fort und übernimmt das deutsche Krebsforschungsunternehmen Tubulis für bis zu fünf Milliarden Dollar. Die Transaktion zeigt, wie... ► Artikel lesen | |
| BB BIOTECH | 48,350 | 0,00 % | Dividenden als Portfolio-Anker: Alte Bekannte Sanofi und BB Biotech - Geheimtipp RE Royalties | In einem Marktumfeld, das von strukturellen Umbrüchen geprägt ist, rückt die Stabilität des Portfolios in den Fokus. Analysten von J.P. Morgan betonen, dass der Schutz von Buchgewinnen der vergangenen... ► Artikel lesen | |
| MEDIGENE | 0,025 | -18,83 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MODERNA | 43,330 | -0,30 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| PAION | 0,051 | -19,84 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 2,668 | -1,11 % | EXKLUSIV zu Valneva: Analysten sehen massives Kurspotenzial - Die Chance die sich zum Wochenstart ergibt | ||
| AMGEN | 299,00 | -0,10 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| EPIGENOMICS | 0,920 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 6,860 | -1,01 % | Activist investor revives campaign to overhaul Novavax board | ||
| BIOGEN | 147,04 | -0,28 % | Biogen to acquire Apellis in $5.6bn deal | ||
| BIOFRONTERA | 2,610 | +2,35 % | BIOFRONTERA AG im Abwärtsmodus - ruhige Einordnung | ||
| HEIDELBERG PHARMA | 2,810 | +3,31 % | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Sonstiges
Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest
09.04.2026... ► Artikel lesen | |
| ILLUMINA | 102,88 | -0,23 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen |
Das Unternehmen ALTAMIRA THERAPEUTICS LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALTAMIRA THERAPEUTICS LTD finden Sie auf Wallstreet Online.